SEC Filing | Abbott Laboratories

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

WOODGRIFT RANDEL WILLIAM

(Last)

(First)

(Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK

60064

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2019

3. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Senior Vice President

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares without par value	42,284	D
Common shares without par value	2,634⁽¹⁾	I	Profit Sharing Trust

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option (right to buy)⁽²⁾	02/20/2016	02/19/2025	Common shares	47,226	47	D
Option (right to buy)⁽³⁾	02/19/2017	02/18/2026	Common shares	83,333	38.4	D
Option (right to buy)⁽⁴⁾	02/17/2018	02/16/2027	Common shares	53,271	44.4	D
Option (right to buy)⁽⁵⁾	02/16/2019	02/15/2028	Common shares	69,605	59.94	D
Option (right to buy)⁽⁶⁾	02/22/2020	02/21/2029	Common shares	42,009	75.9	D

Explanation of Responses:

1. Balance in the Abbott Laboratories Stock Retirement Trust as of April 1, 2019.

2. Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 15,742 on February 20, 2016, 15,742 on February 20, 2017, and 15,742 on February 20, 2018.

3. Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 27,778 on February 19, 2017, 27,777 on February 19, 2018, and 27,778 on February 19, 2019.

4. Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of which 17,757 and 17,757 became exercisable on February 17, 2018 and February 17, 2019, respectively, and 17,757 becomes exercisable on February 17, 2020.

5. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of which 23,202 became exercisable on February 16, 2019 and 23,201 and 23,202 becomes exercisable on February 16, 2020 and February 16, 2021, respectively.

6. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,003 on February 22, 2020, 14,003 on February 22, 2021, and 14,003 on February 22, 2022.

	Jessica H. Paik, by power of attorney for Randel W. Woodgrift	04/03/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Exhibit 24.1


POWER OF ATTORNEY


The undersigned constitutes and appoints HUBERT L. ALLEN, JESSICA
H. PAIK, and AARON N. RICE, and each of them individually, as the
undersigned's true and lawful attorney-in-fact and agent, with
full power of substitution and re-substitution, for the
undersigned and in the undersigned's name, place and stead,
to prepare and sign any and all Securities and Exchange Commission
("SEC") Notices of Proposed Sales of Securities pursuant to Rule 144
under the Securities Act of 1933 on Form 144, all SEC statements
on Forms 3, 4 and 5 as required under Section 16(a) of the Securities
Exchange Act of 1934, including a Form ID and any other documents
necessary to obtain codes and passwords necessary to make electronic
filings, and any amendments to such forms, and to file the same with
all exhibits thereto, and other documents in connection therewith,
with the SEC, granting unto said attorney-in-fact and agent full
power and authority to do and perform each act and thing requisite,
necessary or desirable to be done under said Rule 144 and Section
16(a), as fully for all intents and purposes as the undersigned
might or could do in person, hereby ratifying and confirming all
that said attorney-in-fact and agent may lawfully do or cause to be
done by virtue hereof.

A copy of this power of attorney shall be filed with the SEC.  The
authorization set forth above shall continue in full force and effect
until the undersigned is no longer required to file Forms 144, 3, 4, or
5 or if earlier, until the undersigned revokes such authorization by
written instructions to the attorney-in-fact.



Date:  March 29, 2019

/s/ Randel W. Woodgrift
Signature of Reporting Person

Randel W. Woodgrift


Abbott Laboratories
100 Abbott Park Road
Abbott Park, IL 60064